Skip to main content

Travere Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August:

2024 Wedbush PacGrow Healthcare Conference
Tuesday, August 13, 2024, at 2:30 p.m. ET

Canaccord Genuity 44th Annual Growth Conference
Wednesday, August 14, 2024, at 12:30 p.m. ET

A live webcast of the Canaccord Genuity 44th Annual Growth Conference presentation will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Contact:

Investors:
888-969-7879                                        
IR@travere.com
Media:
888-969-7879                                        
mediarelations@travere.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.84
-1.79 (-0.85%)
AAPL  273.88
-0.35 (-0.13%)
AMD  205.19
-5.68 (-2.69%)
BAC  52.44
+0.75 (1.45%)
GOOG  307.09
-5.94 (-1.90%)
META  658.80
+5.11 (0.78%)
MSFT  404.57
+3.97 (0.99%)
NVDA  188.58
-6.98 (-3.57%)
ORCL  149.93
+2.04 (1.38%)
TSLA  412.06
-5.34 (-1.28%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.